Patients with cellulitis or erysipelas without systemic features who are at increased risk of MRSA infection
For patients with cellulitis or erysipelas without systemic features who are at increased risk of MRSA infection use:
1trimethoprim+sulfamethoxazole 160+800 mg (child 1 month or older: 4+20 mg/kg up to 160+800 mg) orally, 12-hourly. For dosage adjustment in adults with kidney impairment, see trimethoprim+sulfamethoxazole dosage adjustment. See advice on patient review, and modification and duration of therapy trimethoprim + sulfamethoxazole trimethoprim+sulfamethoxazole trimethoprim+sulfamethoxazole
OR
2clindamycin 450 mg (child: 10 mg/kg up to 450 mg) orally, 8-hourly1. See advice on patient review, and modification and duration of therapy. clindamycin clindamycin clindamycin
1 An oral liquid formulation of clindamycin is not commercially available; for formulation options for children or people with swallowing difficulties, see Don’t Rush to Crush, which is available for purchase from the Advanced Pharmacy Australia website or through a subscription to eMIMSplus.Return